NCOA7

Across TCGA pan-cancer cohorts, NCOA7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NCOA7 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NCOA7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NCOA7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where NCOA7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.778	0.313	<.001	62	view →
PDAC	DFS	Median	All	0.880	0.571	<.001	43	view →
CCRCC	OS	Tertile	All	0.946	0.726	<.001	41	view →
LSCC	DFS	Quartile	II,III,IV	0.399	0.875	.004	3	view →
GBM	DFS	Median	All	0.817	0.674	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NCOA7–LUAD (DFS)

Open the LUAD breakdown →